Regenerative spinal fusion implant lands 2nd FDA breakthrough designation

Biologics

Theradaptive's OsteoAdapt SP spinal implant received FDA breakthrough designation for posterolateral spinal fusion.

The device was indicated to treat degenerative disc disease, spondylolisthesis or retrolisthesis, according to a Feb. 15 news release. In November, the device got breakthrough designation for transforaminal lumbar interbody spinal fusion for degenerative disc disease, spondylolisthesis or retrolisthesis.

Breakthrough designation allows Theradaptive priority review and interactive communications with the FDA during the premarket review process.

Subscribe to the following topics: theradaptiveosteoadaptimplantbreakthrough designation

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

Thank you so much for your interest in our content. Please register to access this complimentary archived content. By registering, you will receive our newsletter which can be opted out of at any time.

 

 

Already Registered? Click here to confirm.